Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Mar 24, 2021; 12(3): 164-182
Published online Mar 24, 2021. doi: 10.5306/wjco.v12.i3.164
Published online Mar 24, 2021. doi: 10.5306/wjco.v12.i3.164
Overview of recent advances in metastatic triple negative breast cancer
David O'Reilly, Maha Al Sendi, Catherine M Kelly, Department of Medical Oncology, Mater Misericordiae University Hospital, Dublin 1, Ireland
Author contributions: O'Reilly D wrote the main body of the manuscript; Sendi MA wrote the section on targeted therapies and reviewed the manuscript; Kelly CM provided guidance in the structure of the manuscript and reviewed the manuscript as the senior author.
Conflict-of-interest statement: The authors have no conflict of interests to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: David O'Reilly, MBChB, MRCP, Academic Fellow, Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 1, Ireland.
Received: November 26, 2020
Peer-review started: November 26, 2020
First decision: December 11, 2020
Revised: January 2, 2021
Accepted: March 1, 2021
Article in press: March 1, 2021
Published online: March 24, 2021
Processing time: 104 Days and 16.3 Hours
Peer-review started: November 26, 2020
First decision: December 11, 2020
Revised: January 2, 2021
Accepted: March 1, 2021
Article in press: March 1, 2021
Published online: March 24, 2021
Processing time: 104 Days and 16.3 Hours
Core Tip
Core Tip: Despite recent advances, chemotherapy remains integral to the management of advanced triple negative breast cancer. Immunotherapy and poly (adenosine diphosphate-ribose) polymerase inhibitors have shown much promise but have yet to demonstrate a proven overall survival benefit in this disease. Antibody drug conjugates and other targeted therapies may ultimately prove to be the next frontier in treating this illness.